Fennec Pharmaceuticals Stock Performance

FENC Stock  USD 8.42  0.22  2.68%   
Fennec Pharmaceuticals has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.31, which means possible diversification benefits within a given portfolio. As returns on the market increase, Fennec Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Fennec Pharmaceuticals is expected to be smaller as well. Fennec Pharmaceuticals right now shows a risk of 2.49%. Please confirm Fennec Pharmaceuticals total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to decide if Fennec Pharmaceuticals will be following its price patterns.

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Fennec Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound basic indicators, Fennec Pharmaceuticals is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more

Actual Historical Performance (%)

One Day Return
2.68
Five Day Return
6.05
Year To Date Return
9.64
Ten Year Return
(29.83)
All Time Return
(29.83)
Last Split Factor
1:3
Last Split Date
2014-09-09
1
Acquisition by Raykov Rosty of 5208 shares of Fennec Pharmaceuticals subject to Rule 16b-3
12/01/2025
2
Fennec Pharmaceuticals Reports Positive Results for PEDMARK in Japan - MSN
12/03/2025
3
Disposition of 1000000 shares by Southpoint Capital Advisors Lp of Fennec Pharmaceuticals at 7.5 subject to Rule 16b-3
12/24/2025
4
Major Investor Makes a Bold Exit Move in Fennec Pharmaceuticals - TipRanks
12/30/2025
5
Disposition of 10312 shares by Raykov Rosty of Fennec Pharmaceuticals at 7.6 subject to Rule 16b-3
01/02/2026
6
Acquisition by Robert Andrade of 14184 shares of Fennec Pharmaceuticals at 2.45 subject to Rule 16b-3
01/07/2026
7
Acquisition by Robert Andrade of 10000 shares of Fennec Pharmaceuticals at 2.45 subject to Rule 16b-3
01/15/2026
8
Market Insights and Trading Signals - Stock Traders Daily
01/16/2026
9
Disposition of 1775 shares by Rallis Chris A of Fennec Pharmaceuticals at 9.24 subject to Rule 16b-3
01/28/2026
10
Acquisition by Robert Andrade of 1558 shares of Fennec Pharmaceuticals subject to Rule 16b-3
01/30/2026
11
Disposition of 10349 shares by Raykov Rosty of Fennec Pharmaceuticals at 7.76 subject to Rule 16b-3
02/02/2026
12
Disposition of 796 shares by Raykov Rosty of Fennec Pharmaceuticals at 6.04 subject to Rule 16b-3
02/09/2026
13
B.Riley initiates Fennec Pharmaceuticals stock with Buy rating, 16 target - Investing.com
02/12/2026

Fennec Pharmaceuticals Relative Risk vs. Return Landscape

If you would invest  818.00  in Fennec Pharmaceuticals on November 19, 2025 and sell it today you would earn a total of  24.00  from holding Fennec Pharmaceuticals or generate 2.93% return on investment over 90 days. Fennec Pharmaceuticals is currently generating 0.0787% in daily expected returns and assumes 2.4894% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Fennec, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Fennec Pharmaceuticals is expected to generate 1.53 times less return on investment than the market. In addition to that, the company is 3.27 times more volatile than its market benchmark. It trades about 0.03 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.16 per unit of volatility.

Fennec Pharmaceuticals Target Price Odds to finish over Current Price

The tendency of Fennec Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 8.42 90 days 8.42 
near 1
Based on a normal probability distribution, the odds of Fennec Pharmaceuticals to move above the current price in 90 days from now is near 1 (This Fennec Pharmaceuticals probability density function shows the probability of Fennec Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Fennec Pharmaceuticals has a beta of 0.31. This usually indicates as returns on the market go up, Fennec Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Fennec Pharmaceuticals will be expected to be much smaller as well. Additionally Fennec Pharmaceuticals has an alpha of 0.1521, implying that it can generate a 0.15 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Fennec Pharmaceuticals Price Density   
       Price  

Predictive Modules for Fennec Pharmaceuticals

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Fennec Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
5.948.4310.92
Details
Intrinsic
Valuation
LowRealHigh
7.279.7612.25
Details
5 Analysts
Consensus
LowTargetHigh
13.9115.2916.97
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.03-0.03-0.03
Details

Fennec Pharmaceuticals Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Fennec Pharmaceuticals is not an exception. The market had few large corrections towards the Fennec Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Fennec Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Fennec Pharmaceuticals within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.15
β
Beta against Dow Jones0.31
σ
Overall volatility
0.27
Ir
Information ratio 0.04

Fennec Pharmaceuticals Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Fennec Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Fennec Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
The company reported the previous year's revenue of 47.54 M. Net Loss for the year was (436 K) with profit before overhead, payroll, taxes, and interest of 36.12 M.
Fennec Pharmaceuticals has a frail financial position based on the latest SEC disclosures
About 13.0% of the company shares are held by company insiders
Latest headline from news.google.com: B.Riley initiates Fennec Pharmaceuticals stock with Buy rating, 16 target - Investing.com

Fennec Pharmaceuticals Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Fennec Stock often depends not only on the future outlook of the current and potential Fennec Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Fennec Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding27.3 M
Cash And Short Term Investments26.6 M

Fennec Pharmaceuticals Fundamentals Growth

Fennec Stock prices reflect investors' perceptions of the future prospects and financial health of Fennec Pharmaceuticals, and Fennec Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fennec Stock performance.

About Fennec Pharmaceuticals Performance

By analyzing Fennec Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Fennec Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Fennec Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Fennec Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 139.74  132.75 
Return On Tangible Assets(0.01)(0.01)
Return On Capital Employed 0.06  0.06 
Return On Assets(0.01)(0.01)
Return On Equity 0.07  0.07 

Things to note about Fennec Pharmaceuticals performance evaluation

Checking the ongoing alerts about Fennec Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fennec Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
The company reported the previous year's revenue of 47.54 M. Net Loss for the year was (436 K) with profit before overhead, payroll, taxes, and interest of 36.12 M.
Fennec Pharmaceuticals has a frail financial position based on the latest SEC disclosures
About 13.0% of the company shares are held by company insiders
Latest headline from news.google.com: B.Riley initiates Fennec Pharmaceuticals stock with Buy rating, 16 target - Investing.com
Evaluating Fennec Pharmaceuticals' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Fennec Pharmaceuticals' stock performance include:
  • Analyzing Fennec Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fennec Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
  • Examining Fennec Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Fennec Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fennec Pharmaceuticals' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Fennec Pharmaceuticals' stock. These opinions can provide insight into Fennec Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Fennec Pharmaceuticals' stock performance is not an exact science, and many factors can impact Fennec Pharmaceuticals' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Fennec Stock analysis

When running Fennec Pharmaceuticals' price analysis, check to measure Fennec Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fennec Pharmaceuticals is operating at the current time. Most of Fennec Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Fennec Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fennec Pharmaceuticals' price. Additionally, you may evaluate how the addition of Fennec Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance